2021 was a year full of changes and challenges. We all lived through a continuation of the COVID-19 pandemic while researchers raced to develop new cures and treatments. With collaboration and diligence, researchers at Pfizer developed the COVID-19 vaccine, an mRNA vaccine and first of its kind. Sanguine studies helped facilitate COVID-19 research that made development of the Pfizer vaccine possible (check out the published study here).
Aside from COVID-19 research progress, Sanguine made advancements in other areas of medicine as well. Sanguine completed 111 research studies relating to over 60 medical conditions such as lupus, Crohn’s disease, multiple sclerosis, and sickle cell disease. With our network of phlebotomists nationwide, we were able to make clinical research more convenient and accessible for research participants. Furthermore, Scientists published findings relating to conditions like HIV, lupus, Alzheimer’s disease, and psoriasis. Learn more about these findings and studies Sanguine has collaborated on by checking out our publications page.
Sanguine has a community of over 40k+ research participants and this year, an additional 1,000 members signed up. With greater research participation, we can transform treatment development research. We can help researchers develop more effective personalized treatments with fewer side effects.
This past year, we continued to publish relevant blogs to provide our readers resources and value because we believe in a well-rounded approach to health management. Check out our patient blog here.
In 2022, we will persist with our mission of empowering patients to participate in research and make a difference for the conditions that matter most to them. We will continue our patient-centric approach to clinical research by offering non-invasive, at-home studies. Together, we will continue to revolutionize medicine.